A First-in-Human Phase 1/2a Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of FF-10101-01 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase of Trial: Phase I/II
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs FF-10101-01 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; First in man
- Sponsors FujiFilm Pharmaceuticals USA
- 08 Oct 2019 Planned End Date changed from 1 Jan 2020 to 1 Jan 2023.
- 08 Oct 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2022.
- 24 Jun 2017 New trial record